Replay CEO Lachlan MacKinnon (L) and president Adrian Woolfson

Mak­er of new gene ther­a­py vec­tor launch­es its sec­ond com­pa­ny, look­ing to ze­ro in on rare skin con­di­tions

The hub-and-spoke biotech Re­play, which came on­to the scene with $55 mil­lion in seed cap­i­tal and a vi­sion to launch four com­pa­nies around its gene de­liv­ery plat­form, has al­ready launched one com­pa­ny this year, but it is not look­ing to slow down as the year starts to wrap up.

Re­play an­nounced on Mon­day that the biotech is launch­ing Telar­ia, a gene ther­a­py com­pa­ny tar­get­ing rare skin dis­eases. The top ther­a­py in Telar­ia’s pipeline is a treat­ment for re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa (RDEB). This al­so marks the sec­ond of the four spin­offs that Re­play is plan­ning to launch by lever­ag­ing its “high pay­load ca­pac­i­ty” her­pes sim­plex virus (HSV) de­liv­ery vec­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.